Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial.
PAPERS | January 14-20, 2023 | |
Source: Headache 2023 Jan 18; . doi: 10.1111/head.14439Authors: Ashina M, Tepper SJ, Reuter U, Blumenfeld AM, Hutchinson S, Xia J, Miceli R, Severt L, Finnegan M, Trugman JM
To assess long-term safety, tolerability, and efficacy of once-daily oral atogepant 60 mg in adults with migraine.
Pubmed ID: http://www.ncbi.nlm.nih.gov/pubmed/36651532?dopt=Abstract